VOOLT Spolka Akcyjna
1.46
PLN
+0.02
(+1.39%)
ISIN
PLNVVIS00016
Return %
Stock
S&P 500
1Y
-36.52
14.20
3Y
-0.68
81.12
5Y
-62.80
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Marek Stachura
- Sector
- Electronic technology
- Industry
- Semiconductors
- Address
- Warsaw Poland
- IPO Date
- Jul 4, 2013
- Website
- relacje.novavis.pl
- Similar Companies
- Business
- VOOLT Spolka Akcyjna operates as an investment holding and technology company in Poland, currently transitioning its core operations into an evergreen venture investment vehicle focused on high-technology, deeptech, and life sciences sectors. The company's primary business activities, products, and services encompass direct equity investments and growth capital financing for early-stage deeptech and biotechnology ventures; co-investment syndication alongside institutional venture capital funds; portfolio company incubation and commercialization advisory; turnkey development, engineering, and installation of rooftop and ground-mounted photovoltaic systems; supply and integration of battery energy storage solutions; deployment of electric vehicle charging infrastructure; distribution of residential and commercial heat pumps; digital brokerage and retail distribution of clean energy components via specialized online sales platforms; and technical consulting for renewable energy projects. Founded in 2012 and headquartered in Warsaw, Poland, the company trades on the NewConnect alternative trading market of the Warsaw Stock Exchange under the ticker symbol VLT. In recent developments, the company concluded a comprehensive strategic review that resulted in a major operational pivot away from legacy solar retail contracting toward dedicated deeptech and biotech venture investing in collaboration with Rubicon Partners. As part of this reorganization, the company initiated formal corporate actions to change its business name from VOOLT Spolka Akcyjna to R Ventures II Spolka Akcyjna. Further executing its new strategy, the company completed direct equity investments into Polish biotechnology innovators, including acquiring a stake in pharmaceutical formulation developer Pikralida and deploying 1.2 million PLN to acquire an approximate 5% equity interest in Vaxican sp. z o.o., an oncology biotechnology company developing enveloped virus-like particle therapeutic vaccines. Additionally, the company announced strategic intentions to upscale its capital base and pursue a future listing transfer from NewConnect to the regulated main market of the Warsaw Stock Exchange.